BioSpace News Archive

Alvotech announced that its commercialization partner Fuji Pharma Co., Ltd. has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies’ exclusive commercialization partnership.

Rockwell Medical, Inc. announced that it will release its financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022.

Athira Pharma, Inc. today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton (ATH-1017) in patients with mild-to-moderate Alzheimer’s disease (AD).

The Intelligence Advanced Research Projects Activity (IARPA) and Ginkgo Bioworks today announced the completion of IARPA’s Finding Engineering-Linked Indicators (FELIX) program.

Cardiovascular Systems, Inc. announced today the full market release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems (2.00 Max Crown).

Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific research programs.

Qu Biologics Inc. is pleased to announce that it is receiving advisory services and research and development funding of up to $6,659,050 from the National Research Council of Canada Industrial Research Assistance Program to support the implementation and completion of a Phase II randomized, placebo-controlled clinical trial of QBKPN SSI, a first-in-class immune modulator designed to optimize immunity and barrier function in the lungs.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol and bio-identical progesterone continuously over a 28-day period as part of a hormone therapy (HT) regimen.

Solid Biosciences, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), presented additional data characterizing AAV-SLB101, a novel adeno-associated virus (AAV) vector designed for improved transduction efficiency and biodistribution to muscle cells.

ProPhase Labs, Inc. today announced that its wholly owned subsidiary, Nebula Genomics, Inc., has added Russ B. Altman, M.D., Ph.D to its Advisory Board.